Cibiem Inc.

Article preview from Start-Up - June, 2013

Cibiem Inc.’s catheter-based CBM system is designed to modulate the carotid body, a tiny group of chemoreceptors located at the fork of the carotid artery that helps regulate respiratory activity. The start-up believes its technology could mean new treatment possibilities for a broad range of diseases including heart failure, where it could address the remodeling that takes place as well as alleviate such symptoms as breathlessness.

Cibiem Inc.

Article preview from Start-Up - June, 2013

Balance is important in all aspects of a person's life, including within one's autonomic nervous system. The sympathetic nervous system (SNS) in particular plays a major role in the regulation of cardiopulmonary, renal, and arterial function. In heart failure, SNS activation is associated with remodeling of the left ventricle, worsening signs of HF, and shortened life expectancy. Modulation of SNS activity may be able to impact this syndrome of events, which today affects about six million Americans and costs the health care system more than $30 billion each year. Venture-backed start-up Cibiem Inc. is developing a first-of-its-kind device for modulating SNS activity that it hopes can ultimately change the treatment paradigm for a broad range of devastating diseases, including HF.

Currently based in New York City but moving its headquarters to California's Bay Area later this year, Cibiem was co-founded by Mark Gelfand (Cibiem's chief technical officer) and cardiologist Howard Levin (chief scientific officer). The two, Gelfand with an engineering background and Levin a specialist in HF, spun the company out of their cardiorenal and cardiopulmonary technology-focused incubator, Coridea, in October of last year. They are known for going after big ideas, and developing novel device technologies that get at the physiological origin of a disease state. Since its inception in 2003, Coridea has successfully launched six companies, including CHF Solutions Inc. (acquired by Gambro in 2010), Ardian Inc. (acquired by Medtronic for $800 million in 2010), and Respicardia Inc. (formerly Cardiac Concepts). The Cibiem management team also includes Levin and Gelfand's long-time collaborator Paul Sobotka, MD, as chief medical officer, a cardiologist who also was a member of the CHF Solutions, Respicardia, and Ardian teams.

Continued...

To read this article in its entirety, purchase now, as a PDF and recieve it immediately via email. Or get it free when you subscribe to Start-Up.

About Start-Up

No publication reviews leading edge companies and technology better than Start-Up. Each issue of Start-Up profiles the most important new product companies, identifies the hottest technology areas, reviews funds flowing into private companies and investment trends, and reports on university tech transfer licensing. Industries covered: pharmaceuticals, biotechnology, medical equipment & devices, and in vitro diagnostics.

Plus:
To find out about more about more about Elsevier Business Intelligence's medical device publications and databases, multi-user access and/or advertising with Medical Devices Today, please contact Kristy Kennedy at (480) 985-9512